Literature DB >> 12851486

Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.

Jiyong Liang1, Joyce M Slingerland.   

Abstract

As its role in tumor progression emerges, the PI3K/PKB (Akt) pathway presents an appealing cancer therapeutic target. Recent studies have investigated the mechanisms underlying the tumor-promoting effects of this pathway. PKB triggers a network that positively regulates G1/S cell cycle progression through inactivation of GSK3-beta, leading to increased cyclin D1, and inhibition of Forkhead family transcription factors and the tumor suppressor tuberin (TSC2), leading to reduction of p27Kip1. The identification of p21Waf1/Cip1 and p27Kip1 as novel substrates of PKB provided new insights into mechanisms whereby hyperactivation of this lipid signaling pathway may lead to cell cycle deregulation in human cancers. The PI3K pathway may also play a key role in the G2/M transition and its constitutive activation may lead to defects in DNA damage checkpoint control.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12851486

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  310 in total

1.  The expression of Akt and ERK1/2 proteins decreased in dexamethasone-induced intrauterine growth restricted rat placental development.

Authors:  Asli Ozmen; Gozde Unek; Dijle Kipmen-Korgun; Emin Turkay Korgun
Journal:  J Mol Histol       Date:  2011-04-23       Impact factor: 2.611

2.  Oxidation of Akt2 kinase promotes cell migration and regulates G1-S transition in the cell cycle.

Authors:  Revati Wani; N Sharmila Bharathi; Jeffrey Field; Allen W Tsang; Cristina M Furdui
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

3.  Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition.

Authors:  Míriam Tarrado-Castellarnau; Roldán Cortés; Miriam Zanuy; Josep Tarragó-Celada; Ibrahim H Polat; Richard Hill; Teresa W M Fan; Wolfgang Link; Marta Cascante
Journal:  Pharmacol Res       Date:  2015-11-04       Impact factor: 7.658

Review 4.  Glucocorticoid-Induced Osteoporosis.

Authors:  Baruch Frenkel; Wendy White; Jan Tuckermann
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

5.  MEF2D deficiency in neonatal cardiomyocytes triggers cell cycle re-entry and programmed cell death in vitro.

Authors:  Nelsa L Estrella; Amanda L Clark; Cody A Desjardins; Sarah E Nocco; Francisco J Naya
Journal:  J Biol Chem       Date:  2015-08-20       Impact factor: 5.157

6.  Combined Systemic Disruption of MET and Epidermal Growth Factor Receptor Signaling Causes Liver Failure in Normal Mice.

Authors:  Anastasia Tsagianni; Wendy M Mars; Bharat Bhushan; William C Bowen; Anne Orr; John Stoops; Shirish Paranjpe; George C Tseng; Silvia Liu; George K Michalopoulos
Journal:  Am J Pathol       Date:  2018-07-20       Impact factor: 4.307

7.  The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.

Authors:  Xavier Leleu; Xiaoying Jia; Judith Runnels; Hai T Ngo; Anne-Sophie Moreau; Mena Farag; Joel A Spencer; Costas M Pitsillides; Evdoxia Hatjiharissi; Aldo Roccaro; Garrett O'Sullivan; Douglas W McMillin; Daisy Moreno; Tanyel Kiziltepe; Ruben Carrasco; Steven P Treon; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2007-08-30       Impact factor: 22.113

Review 8.  Molecular pathways: HER3 targeted therapy.

Authors:  Kinisha Gala; Sarat Chandarlapaty
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

Review 9.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

10.  Involvement of the phosphoinositide 3-kinase/Akt pathway in apoptosis induced by capsaicin in the human pancreatic cancer cell line PANC-1.

Authors:  Jian-Hong Zhang; Fu-Ji Lai; Hui Chen; Jiang Luo; Ri-Yuan Zhang; He-Qi Bu; Zhao-Hong Wang; Hong-Hai Lin; Sheng-Zhang Lin
Journal:  Oncol Lett       Date:  2012-10-24       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.